Artefenomel

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Artefenomel
Accession Number
DB11809
Description

Artefenomel has been investigated for the treatment of Malaria.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 469.622
Monoisotopic: 469.28282336
Chemical Formula
C28H39NO5
Synonyms
Not Available
External IDs
  • OZ-439
  • OZ439

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetophenazineThe risk or severity of QTc prolongation can be increased when Artefenomel is combined with Acetophenazine.
AlimemazineThe risk or severity of QTc prolongation can be increased when Artefenomel is combined with Alimemazine.
ArtemetherThe risk or severity of QTc prolongation can be increased when Artefenomel is combined with Artemether.
ButaperazineThe risk or severity of QTc prolongation can be increased when Artefenomel is combined with Butaperazine.
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Artefenomel is combined with Chlorpromazine.
DapsoneThe risk or severity of adverse effects can be increased when Artefenomel is combined with Dapsone.
FluphenazineThe risk or severity of QTc prolongation can be increased when Artefenomel is combined with Fluphenazine.
LumefantrineThe risk or severity of QTc prolongation can be increased when Artefenomel is combined with Lumefantrine.
MesoridazineThe risk or severity of QTc prolongation can be increased when Artefenomel is combined with Mesoridazine.
MethotrimeprazineThe risk or severity of QTc prolongation can be increased when Artefenomel is combined with Methotrimeprazine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Artefenomel MesylatePXW0Q9H3IJ1029939-87-4WQAWGRIICHFPFL-ULBNONRQSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Alkyl aryl ethers / Trioxolanes / Morpholines / Trialkylamines / Dialkyl peroxides / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds
show 1 more
Substituents
1,2,4-trioxolane / Alkyl aryl ether / Amine / Aromatic heteropolycyclic compound / Azacycle / Dialkyl ether / Dialkyl peroxide / Ether / Hydrocarbon derivative / Monocyclic benzene moiety
show 13 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
RIK029813G
CAS number
1029939-86-3
InChI Key
XLCNVWUKICLURR-BGJLAERMSA-N
InChI
InChI=1S/C28H39NO5/c1-3-26(31-14-11-29-9-12-30-13-10-29)4-2-22(1)23-5-7-27(8-6-23)32-28(34-33-27)24-16-20-15-21(18-24)19-25(28)17-20/h1-4,20-21,23-25H,5-19H2/t20?,21?,23-,24?,25?,27+,28?
IUPAC Name
4-(2-{4-[(4's,4''s)-dispiro[adamantane-2,2'-[1,3,5]trioxolane-4',1''-cyclohexane]-4''-yl]phenoxy}ethyl)morpholine
SMILES
C(CN1CCOCC1)OC1=CC=C(C=C1)[[email protected]]1CC[[email protected]]2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3

References

General References
Not Available
PubChem Compound
24999143
PubChem Substance
347828156
ChemSpider
52083295
ChEMBL
CHEMBL4061580

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentMalaria caused by Plasmodium falciparum / Malaria caused by plasmodium vivax1
2CompletedTreatmentPlasmodium Falciparum Infection1
2CompletedTreatmentPlasmodium Infections1
2CompletedTreatmentSchistosomiasis haematobia1
2TerminatedTreatmentPlasmodium Falciparum Infection1
2, 3CompletedTreatmentUncomplicated Plasmodium Falciparum Malaria1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic SciencePlasmodium Infections1
1CompletedOtherPlasmodium Infections1
1CompletedTreatmentHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000467 mg/mLALOGPS
logP4.51ALOGPS
logP5.44ChemAxon
logS-6ALOGPS
pKa (Strongest Basic)6.71ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area49.39 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity128.51 m3·mol-1ChemAxon
Polarizability52.76 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 14:49 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates